Unbiased and Practical Psychopharmacology Updates For Prescribers

Recent articles and videos

The Use of MDMA for PTSD

MDMA (3,4-methylenedioxymethamphetamine) is being studied for treatment-resistant PTSD. This presentation discusses results from clinical and neuroimaging studies.

How to Manage an Agitated Patient?

In this episode, we venture into the psychopharmacology of agitation, with a special focus on psychotic agitation. Dr. Michael Jibson (University of Michigan) and Dr. David Osser (Harvard Medical School) shared clinical pearls to treat this challenging situation.

The Role of Serotonin (5-HT) in Impulsivity/Aggression, Anxiety/Stress and Cognition

This presentation reviews the effects of serotonin receptors (5-HTR) on domains such as impulsivity/aggression, anxiety/stress, and cognition. It also discusses findings from neuroimaging studies involving 5-HT1A and 5-HT2A receptors.

GAD Pharmacotherapy: Augmenting vs Switching in Partial Responders

This presentation discusses how to address partial response to pharmacotherapy in the treatment of GAD. When to switch and when to augment. Dr. Osser gives three options for augmentation.

When to Discontinue Antipsychotics? Reviewing the Evidence

When is the right time to discontinue an antipsychotic in the treatment of schizophrenia? We reviewed the evidence as well as consulting Dr. Ira Glick to help us answer this question.

GAD Pharmacotherapy: Addressing Comorbidities and Special Populations

This presentation discusses the pharmacotherapy of generalized anxiety disorder (GAD). More specifically, it summarizes how to treat comorbid conditions (bipolar disorder, PTSD, substance use, insomnia) and considerations in special populations (elderly and women of childbearing potential).

The Use of Psychotropics in Irritable Bowel Syndrome and Bariatric Surgery

What is the role of antidepressants in the treatment of irritable bowel syndrome? How is drug absorption affected after gastric bypass surgery? This presentation gives practical answers to these questions.

Are Drug Interaction Warnings Influenced by Drug Company Promotion? An Interview with Dr. Jeffrey Mattes

Dr. Jeffrey Mattes, psychiatrist in Princeton, New Jersey speaks about drug interaction warnings that appear during electronic prescribing and how these warnings may be influenced by drug company promotion.
This interview is part of a series covering the 2018 ASCP Annual Meeting.

SSRIs and Bleeding Risk: What Does the Evidence Say?

Do SSRIs increase bleeding risk? This presentation reviews what the current literature says on the risk of GI, perioperative, postpartum and cerebral bleeding with SSRI use.

Do Depression Efficacy Trials Apply to Your Clinical Practice? An Interview with Dr. Mark Zimmerman

Dr. Mark Zimmerman, professor of psychiatry and human behavior at Brown University, speaks about depression efficacy trials and their clinical implications.
This interview is part of a series covering the 2018 ASCP Annual Meeting.

PDF: LAI Antipsychotics

Screenshot 2017 01 07 12.39.54

Free PDF Download

  • New formulations (Aristada, Invega Trinza)
  • Practical dosing tables
Powered by ConvertKit